Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

Saturday, March 26, 2011

Opexa to Present Tovaxin® Data at 2011 American Academy of Neurology Annual Meeting



THE WOODLANDS, Texas (March 23, 2011) - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key Tovaxin® data at the upcoming American Academy of Neurology (AAN) 63rd Annual Meeting to be held in Honolulu, Hawaii April 9-16, 2011.
Clyde Markowitz, M.D., director of the Multiple Sclerosis Center at the University of Pennsylvania, professor of neurology at the University of Pennsylvania School of Medicine in Philadelphia and member of Opexa’s Scientific Advisory Board, will present data from the Phase IIb TERMS clinical trial which demonstrated promising efficacy and safety data in MS patients treated with Tovaxin who were naïve to previous disease modifying therapy.
The data will be presented during a poster session on Thursday, April 14, 2011 from 5:00 to 6:30 p.m. at Poster Session P07, located at P07.192 in the poster hall under the following title: Autologous T-Cell Immunotherapy (Tovaxin) in Treatment-Naïve Patients with Active Relapsing-Remitting Multiple Sclerosis.
Established in 1948, the American Academy of Neurology is an international professional association of more than 22,500 neurologists and neuroscience professionals. The 63rd Annual Meeting will be held in Honolulu, April 9 to April 16, 2011, and will highlight the latest in neurologic research through over 2,000 scientific research presentations. More than 10,000 people are expected to attend the meeting this year.
****************************************************************
"Providing You with 'MS Views and News'is what we do"
.
Remain CURRENT with educational information of
 Multiple Sclerosis when registered at
the MS Views and News  website.
***************************************************************************************
 Please donate  - all contributions are tax deductible -
***************************************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

Novartis’s Gilenya MS Pill to Cost EU22,000 a Year in Germany


By Eva von Schaper - Mar 25, 2011

Novartis AG (NOVN)’s multiple sclerosis pill Gilenya will cost 1,850 euros ($2,620) a month in Germany, according to a company spokesman.
Novartis has set an annual wholesale price of about 22,000 euros for the drug, Eric Althoff, a spokesman for the Basel, Switzerland-based company, said by phone today. Germany is usually used as an indicator for pricing in other European countries, he said.
Gilenya, the first multiple sclerosis pill on the market, will be more expensive than injectable competitors such as Biogen Idec Inc. (BIIB)’s Avonex, Merck KGaA (MRK)’s Rebif and Teva Pharmaceutical Industries Ltd. (TEVA)’s Copaxone, Althoff said. The pill will be cheaper than Biogen’s Tysabri, Althoff said. Gilenya costs about $48,000 annually in the U.S.
The drug’s German pricing “is based on the more restrictive label and the general cost of therapies in Europe,” Althoff said.
****************************************************************
"Providing You with 'MS Views and News'is what we do"
.
Remain CURRENT with educational information of
 Multiple Sclerosis when registered at
the MS Views and News  website.
***************************************************************************************
 Please donate  - all contributions are tax deductible -
***************************************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

Sativex recommended for approval in six European countries to treat multiple sclerosis



Barcelona, Spain
Friday, March 25, 2011, 
GW Pharmaceuticals plc (AIM:GWP) and Almirall S.A. (ALM) announce the successful completion of the European Mutual Recognition Procedure (MRP) for Sativex oromucosal spray in the treatment of spasticity due to Multiple Sclerosis (MS).

Following initial approvals obtained in the UK and Spain during 2010, the objective of this MRP was to expand the approval of Sativex to six additional European countries. The MRP has now closed successfully with the regulatory authorities in all six countries confirming that Sativex meets their requirements for approval. The countries involved in the MRP and in which Sativex is now expected to be approved are Germany, Italy, Denmark, Sweden, Austria and the Czech Republic.

The next step in the regulatory process involves separate national phases in each country to finalise local wording on product packaging and related documents and also to agree any other country-specific requirements. Following completion of the national step, we expect each country to then issue a national marketing authorisation. We anticipate launch before the end of 2011 in Germany, Denmark and Sweden with the remaining countries expected in 2012.

Following the conclusion of this MRP, a further MRP submission will be made later in 2011 with a view to expanding the approval of Sativex to additional European countries.

****************************************************************
"Providing You with 'MS Views and News'is what we do"
.
Remain CURRENT with educational information of
 Multiple Sclerosis when registered at
the MS Views and News  website.
***************************************************************************************
 Please donate  - all contributions are tax deductible -
***************************************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

Bellingham man with MS scales Mount Baker, helps others cope with the disease


March 25, 2011

To look at lifelong athlete Keith Terry, who climbed Mount Baker last year on his first try, you would never know he has multiple sclerosis.

And that, says the 46-year-old Bellingham resident, is precisely the reason he formed a fundraising team for an MS Walk on Saturday, April 2.

An executive recruiter in the biotech industry, Terry moved to Bellingham three years ago from Long Beach, Calif., with his wife, Deborah, and their 16-year-old daughter, Maddy.

Question: Keith, we sometimes don't know who is living with MS, right?

Answer: There really are people in the community you wouldn't know have MS, yet often have huge medical needs and face financial challenges.

Q: What's been your experience?

A: MS usually strikes people in their 20s and 30s. Ten years ago, I thought I was having a heart attack when I became numb in my upper body. But I was told in the emergency room that I was not having a heart attack. Over the course of about two weeks my entire torso became numb from my neck to my bellybutton. A spinal tap didn't show anything, but an MRI eventually showed lesions in my brain and cervical spine.

Q: You seem so healthy now.

A: I never know when I'm going to suffer from fatigue, so I have to get enough rest, but I'm really incredibly fortunate. Because I work, I have health insurance and I now can take a daily shot of a medication known as Copaxone. This costs $115 per day.
I used to go a million miles an hour and I had more energy than anyone you could imagine. Now Deborah says I just have normal energy, and I have to be aware of how much I can do in one day.

Read more



****************************************************************
"Providing You with 'MS Views and News'is what we do"
.
Remain CURRENT with educational information of
 Multiple Sclerosis when registered at
the MS Views and News  website.
***************************************************************************************
 Please donate  - all contributions are tax deductible -
***************************************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************